Currently set to Index
Currently set to No Follow

The Challenges of Global Vaccine Distribution

Vaccine manufacturers, distributers, and governments should undertake certain steps to facilitate its widespread adoption as COVID-19-vaccine rollouts commence


232
Share via
2 shares, 232 points
Share via

The Challenges of Global Vaccine Distribution

 

To date, the COVID-19 vaccines of Moderna and the partnership between BioNTech and Pfizer have already received authorizations for emergency use not only in the US and Canada but also in the European Union, the United Kingdom, and several other countries. With this, many frontline workers and priority citizens have received their first doses.

 


Apart from this, vaccines produced by AstraZeneca, Johnson & Johnson, and a handful of other manufacturers across the globe are expected to arrive soon and will be distributed and administrated. This massive global effort has shattered the record for vaccine development since the previous vaccine project that held the fastest development was Merck’s mumps vaccine, which took four and a half years (1963–67).

Certain places around the world have hit some bumps along the way as they continue with their respective COVID-19 programs. These include the accumulation of stockpiles and the slow deployment to vulnerable countries and at-risk groups. Nonetheless, experts are confident that safe and highly efficacious vaccines are reaching the market, and many hope that this will finally be the end of the pandemic. The epidemiological end to the COVID-19 health crisis seemed to be a dream just several months ago, but, thanks to the fast development, approval, and rollout of some vaccines, it is now basically feasible and realizable in parts of the world.

However, although the COVID-19 vaccination program is already underway, there are still several hurdles we must overcome: raw-materials constraints in production scaling, quality-assurance challenges in manufacturing, cold-chain logistics and storage-management challenges, increased labor requirements, wastage at administration facilities, and IT challenges.

Read more  Harvard Talks: HVAC Healthy Buildings During COVID-19

All of these pose a threat to the acceleration of the COVID-19 immunization programs worldwide. But to mitigate such risks, manufacturers, distributers, and governments should undertake certain steps to facilitate its widespread adoption as COVID-19-vaccine rollouts commence, thereby minimizing the challenges associated with the massive global vaccine deployment.

Click below to read the magazine

Click here to download the magazine

Click here to read on Yumpu

Click here to read on ISSUU

Share via


Like it? Share with your friends!

232
Share via
2 shares, 232 points
Robert Bagatsing
Managing Editor and Founder of GineersNow based in Dubai and Manila. Survived marketing at Harvard, Management at AIM and proud Bedan.

0 Comments

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Send this to a friend